Pharmacokinetic Profile of Metformin and SGLT2 Inhibitors alone and in Combination: a Pharmacokinetic Study in Wistar Rats

Objective: To achieve glycemic control, a combination of drugs is eventually necessary, especially the dual therapy SGLT2 inhibitors with metformin. Despite value therapy, understanding pharmacokinetic properties critical. Therefore, this study aimed to conduct combined and isolated administration hypoglycemic understand their properties. Methodology: The was performed by gavage in twenty-five rats that were divided into five groups: metformin alone (60 mg/kg), canagliflozin 20 mg/kg, (20 mg/kg 60 respectively), dapagliflozin 2 (2 respectively). Blood samples collected between 0.25 36 hours postdose quantified an HPLC-MS/MS method. Results: pharmacokinetics showed values lower than those from literature, but most relevant result significant change Cmax (3400 ng/mL), AUC (872.4 ng.min/L) CL/F (72 mL/min/kg) group compared (523 (106.8 (752 mL/min/kg). For canagliflozin, 6116.7 ng/mL observed our similar while clearance (5.1 higher which 3.5 mL/min/kg. Clearance reported as 3.33 mL/min/kg, 4.6 same also published half-life MRT, slightly findings. In general, parameters literature did not simultaneous Conclusion: Dapagliflozin significantly changed disposition metformin, coadministration had no influence on